Results 111 to 120 of about 811,174 (190)
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale +106 more
wiley +1 more source
Background Bruton’s tyrosine kinase (BTK) is an intracellular signaling enzyme that regulates B-lymphocyte and myeloid cell functions. Due to its involvement in both innate and adaptive immune compartments, BTK inhibitors have emerged as a therapeutic ...
Julie Langlois +12 more
doaj +1 more source
New Means and Challenges in the Targeting of BTK
Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders.
Sondhi, Anya K. +3 more
core +1 more source
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia. [PDF]
Targeting BTK has profoundly changed the face of CLL treatment over the past decade. Iterative advances in the cat and mouse game of resistance and redesign have moved BTK inhibitors from covalent to non-covalent and now targeted protein degraders ...
Kipps, Thomas +3 more
core +1 more source
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He +4 more
wiley +1 more source
Waldenström macroglobulinemia (WM) is a rare, indolent lymphoplasmacytic lymphoma characterized by bone marrow infiltration of IgM-secreting lymphoplasmacytic cells and associated with the MYD88(L265P) mutation in over 90% of cases.
Yujing Liang +7 more
doaj +1 more source
Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang +4 more
wiley +1 more source
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 [PDF]
Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies.
Brown, Robert J +54 more
core +1 more source
Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo +8 more
wiley +1 more source
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan +8 more
wiley +1 more source

